Ratings Albemarle Corporation

Equities

ALB

US0126531013

Market Closed - Nyse Other stock markets 04:00:01 2023-12-08 pm EST			5-day change	1st Jan Change
127.99 ^USD	+2.11%		+1.45%	-40.98%

Dec. 07	US IRA is 'cream on top' as Arcadium eyes lithium growth	RE
Dec. 05	UBS Cuts Albemarle Price Target to $130 From $140, Maintains Neutral Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Specialty Chemicals

	1st Jan change	Capi.	ESG Refinitiv
ALBEMARLE CORPORATION	-40.98%	15 020 M $	C+
ECOLAB INC.	+31.99%	54 781 M $	A-
SIKA AG	+10.83%	44 740 M $	A-
GIVAUDAN SA	+19.73%	35 528 M $	B+
EMS-CHEMIE HOLDING AG	+4.55%	17 377 M $	C+
SYMRISE AG	+3.64%	15 832 M $	B+
NITTO DENKO CORPORATION	+31.05%	9 877 M $	A-
EVONIK INDUSTRIES AG	-2.51%	8 760 M $	A
CRODA INTERNATIONAL PLC	-27.82%	8 278 M $	A
HOSHINE SILICON INDUSTRY CO., LTD.	-40.50%	8 144 M $	D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes